Why This Humira Patent Loss Might Not Be What You Think

Published: May 18, 2017

AbbVie Inc. (NYSE: ABBV) watched its shares slide on Wednesday following a ruling from the U.S. Patent and Trade Mark Office Trial and Appeals Board that found in favor of Coherus Biosciences Inc. (NASDAQ: CHRS). Unfortunately for AbbVie, the board ruled in favor of Coherus, which is looking to sell a lower-cost copycat of AbbVie’s blockbuster rheumatoid arthritis drug, Humira.

Back to news